Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors

Cell Chemical Biology

Volumn 24, Issue 11, 2017, Pages 1388-1400.e7

  Niessen, Sherry ^b   Dix, Melissa M ^a   Barbas, Sabrina ^b   Potter, Zachary E ^a   Lu, Shuyan ^b   Brodsky, Oleg ^b   Planken, Simon ^b   Behenna, Douglas ^b   Almaden, Chau ^b   Gajiwala, Ketan S ^b   Ryan, Kevin ^b   Ferre, RoseAnn ^b   Lazear, Michael R ^a   Hayward, Matthew M ^b   Kath, John C ^b   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

cathepsins; chemical probes; covalent inhibitors; kinases; lysosomal accumulation; proteomics; T790M EGFR

Indexed keywords

AFATINIB; CATHEPSIN; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; OSIMERTINIB; PROTEOME; STREPTAVIDIN; 5' NUCLEOTIDASE; CHEK2 PROTEIN, HUMAN; CYSTEINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; RHODAMINE;

A-431 CELL LINE; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GROWTH; FEMALE; HEK293T CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NCI-H1975 CELL LINE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEOMICS; TRANSIENT TRANSFECTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMISTRY; GENETICS; HEK293 CELL LINE; LIVER; LYSOSOME; METABOLISM; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; XENOGRAFT;

5'-NUCLEOTIDASE; ANIMALS; CATHEPSINS; CELL LINE, TUMOR; CHECKPOINT KINASE 2; CYSTEINE; GPI-LINKED PROTEINS; HEK293 CELLS; HUMANS; LIVER; LYSOSOMES; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEOME; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RHODAMINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 85030723605     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.08.017     Document Type: Article

References (61)

1. Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31 (2013), 88–94.
2. Ahn, M.J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.W., Yang, L., Walding, A., Oxnard, G.R., 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J. Thorac. Oncol., 11, 2016, S115.
3. Antoni, L., Sodha, N., Collins, I., Garrett, M.D., CHK2 kinase: cancer susceptibility and cancer therapy—two sides of the same coin?. Nat. Rev. Cancer 7 (2007), 925–936.
4. Backus, K.M., Correia, B.E., Lum, K.M., Forli, S., Horning, B.D., Gonzalez-Paez, G.E., Chatterjee, S., Lanning, B.R., Teijaro, J.R., Olson, A.J., et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534 (2016), 570–574.
5. Barf, T., Kaptein, A., Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 55 (2012), 6243–6262.
6. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
7. Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S., Greenbaum, D., Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem. Biol. 7 (2000), 27–38.
8. Bromme, D., Lecaille, F., Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Investig. Drugs 18 (2009), 585–600.
9. Butterworth, S., Finlay, M.R.V., Ward, R.A., Kadambar, V.K., Chandrashekar, R.C., Murugan, A. & Redfearn, H.M. 2013. 2-(2, 4, 5-substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer. Google Patents.
10. Cheng, H., Nair, S.K., Murray, B.W., Almaden, C., Bailey, S., Baxi, S., Behenna, D., Cho-Schultz, S., Dalvie, D., Dinh, D.M., et al. Discovery of 1-{(3R,4R)-3-[({5-chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyr imidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants. J. Med. Chem. 59 (2016), 2005–2024.
11. Cognetta, A.B. 3rd, Niphakis, M.J., Lee, H.C., Martini, M.L., Hulce, J.J., Cravatt, B.F., Selective N-hydroxyhydantoin carbamate inhibitors of mammalian serine hydrolases. Chem. Biol. 22 (2015), 928–937.
12. Cravatt, B.F., Wright, A.T., Kozarich, J.W., Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77 (2008), 383–414.
13. Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., Orme, J.P., Finlay, M.R., Ward, R.A., Mellor, M.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
14. Desmarais, S., Black, W.C., Oballa, R., Lamontagne, S., Riendeau, D., Tawa, P., Duong, L.T., Pickarski, M., Percival, M.D., Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol. Pharmacol. 73 (2008), 147–156.
15. Fakhoury, S.A., Lee, H.T., Reed, J.E., Schlosser, K.M., Sexton, K.E., Tecle, H., and Winters, R.T. (2005). 4-phenylamino-quinazolin-6-yl-amides. Google Patents.
16. Falgueyret, J.P., Desmarais, S., Oballa, R., Black, W.C., Cromlish, W., Khougaz, K., Lamontagne, S., Masse, F., Riendeau, D., Toulmond, S., Percival, M.D., Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48 (2005), 7535–7543.
17. Finlay, M.R., Anderton, M., Ashton, S., Ballard, P., Bethel, P.A., Box, M.R., Bradbury, R.H., Brown, S.J., Butterworth, S., Campbell, A., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57 (2014), 8249–8267.
18. Fleuren, E.D., Zhang, L., Wu, J., Daly, R.J., The kinome 'at large' in cancer. Nat. Rev. Cancer 16 (2016), 83–98.
19. Furber, M., Tiden, A.K., Gardiner, P., Mete, A., Ford, R., Millichip, I., Stein, L., Mather, A., Kinchin, E., Luckhurst, C., et al. Cathepsin C inhibitors: property optimization and identification of a clinical candidate. J. Med. Chem. 57 (2014), 2357–2367.
20. Greenbaum, D., Medzihradszky, K.F., Burlingame, A., Bogyo, M., Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7 (2000), 569–581.
21. Greenbaum, D., Baruch, A., Hayrapetian, L., Darula, Z., Burlingame, A., Medzihradszky, K.F., Bogyo, M., Chemical approaches for functionally probing the proteome. Mol. Cell Proteomics 1 (2002), 60–68.
22. Hamon, Y., Legowska, M., Herve, V., Dallet-Choisy, S., Marchand-Adam, S., Vanderlynden, L., Demonte, M., Williams, R., Scott, C.J., Si-Tahar, M., et al. Neutrophilic cathepsin C is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases. J. Biol. Chem. 291 (2016), 8486–8499.
23. Hughes, J.P., Rees, S., Kalindjian, S.B., Philpott, K.L., Principles of early drug discovery. Br. J. Pharmacol. 162 (2011), 1239–1249.
24. Inloes, J.M., Hsu, K.L., Dix, M.M., Viader, A., Masuda, K., Takei, T., Wood, M.R., Cravatt, B.F., The hereditary spastic paraplegia-related enzyme DDHD2 is a principal brain triglyceride lipase. Proc. Natl. Acad. Sci. USA 111 (2014), 14924–14929.
25. Johnson, D.S., Weerapana, E., Cravatt, B.F., Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2 (2010), 949–964.
26. Khoh-Reiter, S., Sokolowski, S.A., Jessen, B., Evans, M., Dalvie, D., Lu, S., Contribution of membrane trafficking perturbation to retinal toxicity. Toxicol. Sci. 145 (2015), 383–395.
27. Klijn, C., Durinck, S., Stawiski, E.W., Haverty, P.M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33 (2015), 306–312.
28. Krishnamurty, R., Maly, D.J., Chemical genomic and proteomic methods for determining kinase inhibitor selectivity. Comb. Chem. High Throughput Screen. 10 (2007), 652–666.
29. Lanning, B.R., Whitby, L.R., Dix, M.M., Douhan, J., Gilbert, A.M., Hett, E.C., Johnson, T.O., Joslyn, C., Kath, J.C., Niessen, S., et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10 (2014), 760–767.
30. Lee, J.S., Yoo, Y.H., Yoon, C.N., Small-molecule probes elucidate global enzyme activity in a proteomic context. BMB Rep. 47 (2014), 149–157.
31. Lee, K., Niu, D., Petter, R.C., Baevsky, M.F., and Singh, J. (2015). Heterocyclic compounds and uses thereof. Google Patents.
32. Leproult, E., Barluenga, S., Moras, D., Wurtz, J.M., Winssinger, N., Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J. Med. Chem. 54 (2011), 1347–1355.
33. Linker, R.A., Haghikia, A., Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther. Adv. Chronic Dis. 7 (2016), 198–207.
34. Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S.J., Jones, L.H., Gray, N.S., Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20 (2013), 146–159.
35. Martina, J.A., Diab, H.I., Lishu, L., Jeong, A.L., Patange, S., Raben, N., Puertollano, R., The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci. Signal., 7, 2014, ra9.
36. Nadanaciva, S., Lu, S., Gebhard, D.F., Jessen, B.A., Pennie, W.D., Will, Y., A high content screening assay for identifying lysosomotropic compounds. Toxicol. Vitro 25 (2011), 715–723.
37. Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A., Mann, M., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1 (2002), 376–386.
38. Ong, S.E., Foster, L.J., Mann, M., Mass spectrometric-based approaches in quantitative proteomics. Methods 29 (2003), 124–130.
39. Patricelli, M.P., Nomanbhoy, T.K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18 (2011), 699–710.
40. Planken, S., Behenna, D.C., Nair, S.K., Johnson, T.O., Nagata, A., Almaden, C., Bailey, S., Ballard, T.E., Bernier, L., Cheng, H., et al. Discovery of N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR. J. Med. Chem. 60 (2017), 3002–3019.
41. Potashman, M.H., Duggan, M.E., Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52 (2009), 1231–1246.
42. Roberts, H., White, P., Dias, I., Mckaig, S., Veeramachaneni, R., Thakker, N., Grant, M., Chapple, I., Characterization of neutrophil function in Papillon-Lefevre syndrome. J. Leukoc. Biol. 100 (2016), 433–444.
43. Rosenblum, J.S., Nomanbhoy, T.K., Kozarich, J.W., Functional interrogation of kinases and other nucleotide-binding proteins. FEBS Lett. 587 (2013), 1870–1877.
44. Rostovtsev, V.V., Green, L.G., Fokin, V.V., Sharpless, K.B., A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew. Chem. Int. Ed. 41 (2002), 2596–2599.
45. Sanman, L.E., Bogyo, M., Activity-based profiling of proteases. Annu. Rev. Biochem. 83 (2014), 249–273.
46. Singh, J., Petter, R.C., Baillie, T.A., Whitty, A., The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10 (2011), 307–317.
47. Speers, A.E., Cravatt, B.F., Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11 (2004), 535–546.
48. Spicer, J.F., Rudman, S.M., EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 5 (2010), 245–255.
49. Sun, H., Ren, Y., Hou, W., Li, L., Zeng, F., Li, S., Ma, Y., Liu, X., Chen, S., Zhang, Z., Focusing on probe-modified peptides: a quick and effective method for target identification. Chem. Commun. (Camb) 52 (2016), 10225–10228.
50. Tjin Tham Sjin, R., Lee, K., Walter, A.O., Dubrovskiy, A., Sheets, M., Martin, T.S., Labenski, M.T., Zhu, Z., Tester, R., Karp, R., et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol. Cancer Ther. 13 (2014), 1468–1479.
51. Toomes, C., James, J., Wood, A.J., Wu, C.L., Mccormick, D., Lench, N., Hewitt, C., Moynihan, L., Roberts, E., Woods, C.G., et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat. Genet. 23 (1999), 421–424.
52. Walter, A.O., Sjin, R.T., Haringsma, H.J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3 (2013), 1404–1415.
53. Wang, C., Weerapana, E., Blewett, M.M., Cravatt, B.F., A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles. Nat. Methods 11 (2014), 79–85.
54. Wang, S., Cang, S., Liu, D., Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J. Hematol. Oncol., 9, 2016, 34.
55. Weerapana, E., Wang, C., Simon, G.M., Richter, F., Khare, S., Dillon, M.B., Bachovchin, D.A., Mowen, K., Baker, D., Cravatt, B.F., Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468 (2010), 790–795.
56. Wilson-Grady, J.T., Haas, W., Gygi, S.P., Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61 (2013), 277–286.
57. Winer, E.S., Ingham, R.R., Castillo, J.J., PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 21 (2012), 355–361.
58. Yosaatmadja, Y., Silva, S., Dickson, J.M., Patterson, A.V., Smaill, J.B., Flanagan, J.U., Mckeage, M.J., Squire, C.J., Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J. Struct. Biol. 192 (2015), 539–544.
59. Zannini, L., Delia, D., Buscemi, G., CHK2 kinase in the DNA damage response and beyond. J. Mol. Cell Biol. 6 (2014), 442–457.
60. Zhang, J., Yang, P.L., Gray, N.S., Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9 (2009), 28–39.
61. Zuhl, A.M., Nolan, C.E., Brodney, M.A., Niessen, S., Atchison, K., Houle, C., Karanian, D.A., Ambroise, C., Brulet, J.W., Beck, E.M., et al. Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of beta-secretase inhibitors. Nat. Commun., 7, 2016, 13042.